 | Up a level |
2016
Moskowitz, Craig H., Zinzani, Pier Luigi, Fanale, Michelle A., Armand, Philippe, Johnson, Nathalie A., Radford, John A., Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Gustafson, Eric, Zhang, Yinghua, Ricart, Alejandro Daniel, Balakumaran, Arun and Chen, Robert W. (2016). Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
2012
Chen, Robert W., Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Sievers, Eric L. and Younes, Anas (2012). Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971
Karuturi, Meghan S., Arai, Sally, Chen, Robert W., Gopal, Ajay K., Feng, Lei, Yuan, Ying, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Ramchandren, Radhakrishnan, Bartlet, Nancy L., Cheson, Bruce D., Forero-Torres, Andres, Moskowitz, Craig H., Connors, Joseph M., Fanale, Michelle A., de Vos, Sven, Engert, Andreas, Illidge, Tim, Borchmann, Peter, Morschhauser, Franck, Horning, Sandra J. and Younes, Anas (2012). Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971